Literatura

Pacjenci z zespołem jelita drażliwego wykazują istotne zaburzenia mikroflory jelitowej

1. Ahrné, S., Nobaek, S., Jeppsson, B., Adlerberth, I., Wold, A., and Molin, G. (1998). The normal Lactobacillus flora of healthy human rectal and oral mucosa, J. Appl. Microbiol. 85: 88-94.

2. Kassinen A, Krogius-Kurrika L., Makivuokko H. i wsp. (2007). The Fecal Microbiota of Irritable Bowel Syndrome Patients Differs Significantly From That of Healthy Subjects. Gastroenterology 133; 24-33

3. Molin, G., Jeppsson, B., Ahrné, S., Johansson, M.-L., Nobaek, S., Stahl, M., and Bengmark, S. (1993). Numerical taxonomy of Lactobacillus spp. associated with healthy and diseased mucosa of the human intestines, J. Appl. Bacteriol. 74: 314-323.

Lactobacillus plantarum 299v wydajnie kolonizuje błonę śluzową jelita cienkiego po podaniu doustnym

1. Hütt, P., Shchepetova, J., Loivukene, K., Kullisaar, T. and Mikelsaar, M. (2006). Antagonistic activity of probiotic lactobacilli and bifidobacteria against entero- and urpathogens. Journal of Applied Microbiology 100: 1324-1332

2. Mack, D.R., Michail, S., Wei, S., McDougall L., and Hollingsworth, M.A. (1999).Probiotics inhibit enteropathogenic E.coli adherence in vitro by inducing intestinal mucin gene expression, Am. J. Physiol. 276: G941-G950.

3. Mack, D.R., Ahrné, S., Hyde, L., Wei, S. and Hollingsworth, M.A. (2003). Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut 52: 827-833.

4. Mangell, P., Nejdfors, P., Wang, M., Ahrné, S., Weström, B., Thorlacius, H., and Jeppsson, B. (2002). Lactobacillus plantarum 299v inhibits Escherichia coli-induced intestinal permeability, Digestive Diseases and Sciences 47: 511-516.

Suplementacja Lactobacillus plantarum 299v w zaburzeniach czynnościowych jelit

1. Johansson, M-L., Nobaek, S., Berggren, A., Nyman, M., Björck, I., Ahrné, S., Jeppsson, B., and Molin, G. (1998). Survival of Lactobacillus plantarum DSM 9843 (299v), and effect on the short-chain fatty acid content in faeces after ingestion of a rose-hip drink with fermented oats, Int. J. Fd. Microbiol. 42: 29-38.

2. Niedzielin, K., Kordecki, H., and Birkenfeld, B. (2001). A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299v in patients with irritable bowel syndrome, Eur. J. Gastroenterol. Hepatology 13: 1143-1147.

3. Nobaek, S., Johansson, M-L., Molin, G., Ahrné, S., and Jeppsson, B. (2000). Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome, Am. J. Gastroenterol. 95: 1231- 1238.

4. Sen, S., Mullan, M.M., Parker, T.J., Woolner, J.T., Tarry, S.A. and Hunter, J.O. (2002).Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Digestive Diseases and Sciences 47: 2615-2620

Pozostałe wybrane pozycje literaturowe /Lactobacillus plantarum 299v/


1. Adawi, D., Kasravi, F.B., Molin, G., and Jeppsson, B. (1997). Effect of Lactobacillus supplementation with and without arginine on liver damage and bacterial translocation inan acute liver injury model, Hepatology 25: 642-647.

2. Adawi, D., Molin, G., Ahrné, S., and Jeppsson, B. (2002). Safety of the probiotic strain Lactobacillus plantarum DSM 9843 ( = strain 299v) in an endocarditis Animals model, Microb. Ecol. Health Dis., 14: 50-53.

3. Adlerberth, I., Ahrné, S., Johansson, M-L., Molin, G., Hanson, L-A., and Wold, A.E. (1996). A mannose-specific adherence mechanism in Lactobacillus plantarum conferring binding to the human colonic cell line HT-29, Appl. Environ. Microbiol., 62: 2244-2251. Aguirre, M. and Collins, M.D. (1993). Lactic acid bacteria and human clinical infection, J. Appl. Bacteriol. 75: 95-107.

4. Berggren, A., Söderberg, L., Önning, G., Johansson Hagslätt, M-L. and Axelsson, I. (2003). Intestinal function, microflora and nutrient intake of children after administration of a fermented oat product containing Lactobacillus plantarum DSM 9843 (299v). Microbial Ecology in Health and Disease 15: 160-168.

5. Bukowska, H., Pieczul-Mróz, J., Jastrzebsk, K., Chelstowski, K., and Naruszewicz, M. (1998). Significant decrease in fibrinogen and LDL-cholesterol levels upon supplementation of the diet with Lactobacillus plantarum (ProViva) in subjects with moderately elevated cholesterol concentrations, Atherosclerosis, 137: 437-438.

6. Cunningham-Rundles, S., Ahrné, S., and Bengmark, S. (2000). Probiotics and immune response. Am. J. Gastroenterol. 95 (1, Supplement, 2000): S22-S25.

7. Cunningham-Rundles, S., Ahrné, S., Abuav-Nissbaum, B.S., and Dnistrian, A. (2002).Development of immunocompetence: role of micronutrients and microorganisms,Nutrition Reviews 60 (5): S68-S72.

8. Goossens, D., Jonkers, D., Russel, M., Stobberingh, E., van den Bogaard, A. and Stockbrügger, R. (2003). The effect of Lactobacillus plantarum 299v on the bacterial composition and metabolic activity in faeces of healthy volunteers: a placebocontrolled study on the onset and duration of effects. Alliment. Pharmacol. Ther. 18: 495-505.

9. Goossens, D., Jonkers, D., Russel, M., Thijs, A., van den Bogaard, A., Stobberingh, E. andStockbrügger, R. (2005). Survival of the probiotic, L. plantarum 299v and its effect on thefaecal bacterial flora, with and without gastric acid inhibition. Digestive and Liver Disease37: 44-50.

10. Goossens, D., Jonkers, D., Russel, M., Stobberingh, E. and Stockbrügger, R. (2006a). The effect of a probiotic drink with L. plantarum 299v on the bacterial composition In faeces and mucosal biopsies of rectum and ascending colon. Alimentary Pharmacology & Therapeutics 23: 255-263.

11. Goossens, D., Jonkers, D., Stobberingh, E., Molin, G., Ahrné, S., Russel, M., and Stockbrügger, R. (2006b). The faecal and mucosal bacterial composition of patients with inactive UC: can it be changed by L. plantarum 299v? In: The effect of the probiotic L. plantarum 299v on the intestinal flora: Methodological studies in health and disease. PhDthesis by D. Goossens. Chapter 6. The Nutrition and Toxicology Research Institute Maastricht, Maastricht, 2006.

12. Goossens, D., Jonkers, D., Russel, M., Vaughan, E., Stobberingh, E., and Stockbrügger, R.(2006c). Bowel cleansing with subsequent intake of Lactobacillus plantarum 299v does not change the composition of the faecal flora. Microbial Ecology in Health and Disease. 18: 139-146.

13. Hütt, P., Shchepetova, J., Loivukene, K., Kullisaar, T. and Mikelsaar, M. (2006). Antagonistic activity of probiotic lactobacilli and bifidobacteria against entero- and urpathogens. Journal of Applied Microbiology 100: 1324-1332.

14. Johansson, M.-L., Molin, G., Jeppsson, B., Nobaek, S., Ahrné, S., and Bengmark, S.(1993). Administration of different Lactobacillus strains in fermented oatmeal soup: In vivo colonization of human intestinal mucosa and effect on the indigenous flora, Appl.Environ. Microbiol. 59: 15-20.

15. Johansson, M-L., Nobaek, S., Berggren, A., Nyman, M., Björck, I., Ahrné, S., Jeppsson, B., and Molin, G. (1998). Survival of Lactobacillus plantarum DSM 9843 (299v), and effect on the short-chain fatty acid content in faeces after ingestion of a rose-hip drink with fermented oats, Int. J. Fd. Microbiol. 42: 29-38.

16. Klarin, B., Johansson, M-L., Molin, G., Larsson, A., Jeppsson, B. (2005). Adhesion of the probiotic bacterium Lactobacillus plantarum 299v onto the gut mucosa in critically ill patients: a randomised open trial. Critical Care 9: R285-R293.

17. Liu, Q., Nobaek, S., Adawi, D., Mao, Y., Wang, M., Molin, G., Ekelund, M., and Jeppsson, B. (2001). Administration of Lactobacillus plantarum 299v reduces side effects of external radiation on colonic anastomotic healing in an experimental model, Colorectal Disease 3: 245-252.

18. Mangiante, G, Colucci, G., Canepari, P., Bassi, C., Nicoli, N., Casaril, A., Marinello, P., and Bengmark, S. (2001). Lactobacillus plantarum reduces infection of pancreatic necrosis in experimental acute pancreatitis, Digest. Surg. 18: 47-50.

19. Mao, Y., Nobaek, S., Adawi, D., Molin, G., and Jeppsson, B. (1997). Comparison of the effects of different Lactobacillus strains in reducing bacterial translocation on Methotrexate induced enterocolitis in rats, Digest. Surg. 14: 284-291.

20. McCracken, V.J, Chun, T., Baldeón, M.E., Ahrné, S., Molin, G., Mackie, R.I. & Gaskins, H.R. (2002). TNF-α sensitizes HT-29 colonic epithelial cells to intestinal lactobacilli. Experimental Biology and Medicine 227: 665-670.

21. McNaught, C.E., Woodcock, N.P., MacFie, J and Mitchell, C.J. (2002). A prospective randomised study of the probiotic Lactobacillus plantarum 299v on indices of Gut barrier function in elective surgical patients. Gut 51: 827-831.

22. Michail, S. and Abernathy, F. (2002). Lactobacillus plantarum reduces the in vitro secretory response of intestinal epithelial cells to enteropathogenic Escherichia coli infection. Journal of Pediatric Gastroenterology and Nutrition 35: 350-355.

23. Molin, G. (2001). Probiotics in foods not containing milk or milk constituents, with special reference to Lactobacillus plantarum 299v, Am. J. Clin. Nutr. 73 (Iss. 2; Suppl. S): 380S-385S.

24. Molin, G. (2003). The role of Lactobacillus plantarum in foods and in human health. In: Handbook of Fermented Functional Foods. chap. 13; pp. 305-342. E. R. Farnworth (ed).CRC Press, Boca Raton, London, New York, Washington, D.C.

25. Naruszewicz, M., Johansson, M-L., Zapolska-Downar, D., and Bukowska, H. (2002).Effect of Lactobacillus plantarum 299v on cardiovascular disease risk factors in smokers,Am. J. Clin. Nutr., 76: 1249-1255.

26. Niedzielin, K., Kordecki, H., and Birkenfeld, B. (2001). A controlled, doubleblind, randomized study on the efficacy of Lactobacillus plantarum 299v in patients with irritable bowel syndrome, Eur. J. Gastroenterol. Hepatology 13: 1143-1147.

27. Nobaek, S., Johansson, M-L., Molin, G., Ahrné, S., and Jeppsson, B. (2000). Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome, Am. J. Gastroenterol. 95: 1231-1238.

28. Olah, A., Belagyi, T., Issekutz, A., Gamal, M.E. and Bengmark, S. (2002). Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. British Journal of Surgery 89: 1103-1107.

29. Önning, G., Berggren, A., Drevelius, M., Jeppsson, B., Lindberg, A.-M., Johansson Hagslätt, M.-L. (2003). Influence of a drink containing different antioxidants and Lactobacillus plantarum 299v on plasma total antioxidant capacity, selenium staus and faecal microbial flora. International Journal of Food Sciences and Nutrition 54: 281-289.

30. Osman, N., Adawi, D., Ahrne, S., Jeppsson, B. & Molin, G. (2004). Modulation of the effect of dextran sulfate sodium-induced acute colitis by the administration of different probiotic strains of Lactobacillus and Bifidobacterium. Digestive Diseases and Sciences 42: 320-327.

31. Rayes, N., Seehofer, D., Hansen, S., Boucsein, K., Muller, A.R., Serke, S., Bengmark, S. and Neuhaus, P. (2002b). Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation 15:123-127.

32. Schultz, M., Veltkamp, C., Dieleman, L.A., Grenther, W.B., Wyrick, P.B., Tonkonogy, S.L., and Sartor, R.B. (2002). Lactobacillus plantarum 299v in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflamm. Bowl. Dis. 8: 71-80.
33. Sen, S., Mullan, M.M., Parker, T.J., Woolner, J.T., Tarry, S.A. and Hunter, J.O. (2002). Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Digestive Diseases and Sciences 47: 2615-2620.

34. Stjernquist-Desatnik, A., Warfving, H. and Johansson, M-L. (2000). Persistence of Lactobacillus plantarum DSM 9843 on human tonsillar surface after oral administration in fermented oatmeal gruel. Acta Otolaryngol (Suppl.) 543: 215-219.

35. Vanderhoof, J.A., Young, R.J., Murray, N. and Kaufman, S.S. (1998). Treatment strategies for small bowel bacterial overgrowth in short bowel syndrome. Journal of Pedriatric Gastroenterology and Nutrition 27: 155-160.

36. Veltkamp, C., Tonkongy, S.L., Schulz, M. et al. (1999). Lactobacillus plantarum is superior to Lactobacillus GG in preventing colitis in IL-10 deficient mice [Abstract]. Gastroenterology 116: A838.

37. Wullt, M., Johansson Hagslätt, M.-L. and Odenholt, I. (2003). Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficille-associated diarrhoea: A doubleblind placebo-controlled trial. Scandinavian Journal of Infect. Dis. 35: 365-367

38, Whitehead WE et al.: Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002; 122:1140-1156

39. Irvine EJ et al.: Health-related quality of life in functional GI disorders: focus  on constipation and resource utilization. Am J Gastroenterol. 2002;97:1986-93.

40. Damon H, Dumas P, Mion F.: Impact of anal incontinence and chronic constipation on
quality of life. Gastroenterol Clin Biol. 2004;28:16-20.

41. Mayer E. Irritable bowel syndrome. N Engl J Med 2008;358:1692-1699

42. Parkes GC et al.: Gastrointestinal Microbiota in Irritable Bowel Syndrome: Their Role in Pathogenesis and Treatment. Am J Gastroenterol 2008; 103: 1-11

43. Spiller R et al.: Post-infectious irritable bowel syndrome. Curr Opin Gastroenterol 2006; 22:13

44. Spiller R, Garsed K: Post Infectious IBS. Gastroenterology 2009; 136:1979-1988

45. Jakobsson HE, Jernberg C, Andersson AF et al.: Short-Term Antibiotic Treatment Has Differing Long-Term Impacts on the Human Throat and Gut Microbiome. PloS one 2010, vol. 5 (3), e9836

46. Sawant PD., Venkatramant J., Ducrotte P.: Evaluation of Lactobacillus plantarum 299v Efficacy in IBS: Results of a Randomized Placebo-Controlled Trial in 200 Patients. DDW 2010

47. Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B. Alteration of Intestinal Microflora Is Associated With Reduction in Abdominal Bloating and Pain in Patients With Irritable Bowel Syndrome. Am J Gastroenterol 2000; 95 (5): 1232-1238

48. Niedzielin K , Kordecki H, Birkenfeld B: A controlled, double-blind, randomized study on the eficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. European Journal of Gastroenterology & Hepatology 2001, 13:1143±1147

49. Dinan TG, Cryan J, Shanahan F, Keeling PWN, Quigley EMM: IBS: an epigenetic perspective. Nature Reviews Gastroenterology and Hepatology 2010 7, 465-471

50. Jiménez MB Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last? Rev Esp Enferm Dig (Madrid) 2009, Vol. 101, 8, 553-564

51. McFarland LV, Dublin S Meta-analysis of probiotics for the treatment of irritable bowel syndrome World J Gastroenterol 2008 May 7; 14(17): 2650-2661

52. Floch MH, Walker WA, Guandalini S, et al.: Recommendations for Probiotic Use—2008, 2008 J Clin Gastroenterol _ Volume 42, Supp. 2

53. Lyra A, Rinttilä T, Nikkilä J et al.: Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification. 200; Vol 15 (47): 5936-5945

54. Wilson ID: Drugs, bugs, and personalized medicine: Pharmacometabonomics enters the ring. PNAS 2009; vol. 106 , no. 34 14187–14188

55. Hattori M, Taylor TD.: The Human Intestinal Microbiome: A New Frontier of Human Biology DNA Research, 2009; 16, 1–12

56. Erridge C, Duncan SH, Bereswill S,Heimesaat MM: The Induction of Colitis and Ileitis in Mice Is Associated with Marked Increases in Intestinal Concentrations of Stimulants of TLRs 2, 4, and 5. PLoS one, 2010 Vol. 5 (2), e9125

57. Baarlen P, Troost FJ, Hemert S, Meer C, de Vos WM, de Groot PJ, Hooiveld G, Brummer RJ, Kleerebezem M: Differential NF-_B pathways induction by Lactobacillus plantarum in the duodenum of healthy humans correlating with immune tolerance. PNAS , 2009; vol. 106; 7: 2371 –2376

58. Aragon G, Graham DB, Borum M, Doman DB: Probiotic Therapy for Irritable Bowel Syndrome.Gastroenterology & Hepatology 2010, Vol. 6,(1)

59. Barbara G, Stanghellini V, Cremon C, Giorgio RD, Gargano L, Cogliandro R, Pallotti F, Corinaldesi R: Probiotics and Irritable Bowel Syndrome Rationale and Clinical Evidence for Their Use. J Clin Gastroenterol 2008 Vol. (42), Supp. 3, Part 2

60. Ghoshal UC, Park H, Gwee KH: Bugs and irritable bowel syndrome: The good, the bad and the ugly. Journal of Gastroenterology and Hepatology 2010; 25 244–251

61. Dos Santos VM, Muller M, de Vos WM Systems biology of the gut: the interplay of food, microbiota and host at the mucosal interface. Current Opinion in Biotechnology 2010, 21:539–550

62. Ducrotté P.: Microbiota and irritable bowel syndrome. Gastroentérologie Cliniqueet Biologique (2010) 34, Suppl.1, S52—S56

63. Stanghellini V., Barbara G., Cremon C, Cogliandro R, Antonucci A, Gabusi V., Frisoni C., De Giorgio R.,Grasso V, Serra M, Corinaldesi R.: Gut microbiota and related diseases: clinical features. Intern Emerg Med (2010) 5 (Suppl 1):S57–S63

64. Baarlen P, Troost F, Meer C, Hooiveld G, Boekschoten M, Brummer RJM, Kleerebezem M.: Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. Proc Natl Acad Sci U S A. 2010; 1-8

65. Dethlefsen L; Relman DA: Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U SA. 2010

66. Szajewska H.: Advances and Limitations of Evidence-Based Medicine – Impact for Probiotics. Ann Nutr Metab 2010; 57(suppl 1):6–9

67. Chang JY, Talley NJ.: Current and emerging therapies in irritable bowel syndrome: from pathophysiology to treatment. Trends in Pharmacological Sciences 31 (2010) 326– 334

68. Tana C,Umesaki Y., Imaoka A, Handa T., Kanazawa M, Fukudo S: Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil (2010) 22, 512–e115

69. Bibiloni R, Schiffrin EJ: Intestinal Host-Microbe Interactions under Physiological and Pathological Conditions. Int J Inflam. 2010; 2010: 386956.

70. Salzman NH.: Microbiota-immune system interaction: an uneasy alliance. Curr Opin Microbiol 2010, vol. 21

71. Lyte M, Vulchanova L, Brown DR. Stress at the intestinal surface: catecholamines and mucosa-bacteria interactions. Cell Tissue Res. 2011 Jan; 343 (1): 23-32

72. Lakhan SE, Kirchgessner A. Gut inflammation in chronic fatigue syndrome. Nutr Metab (Lond). 2010;7:79

73. O'Mahony SM, Hyland NP, Dinan TG, Cryan JF. Maternal separation as a model of braingut axis dysfunction. Psychopharmacology (Berl). 2010 Oct 1

74. Carroll IM, Chang YH, Park J, Sartor RB, Ringel Y.: Luminal and Mucosal-Associated Intestinal Microbiota in Patients with Diarrhea-Predominant Irritable Bowel Syndrome. Gut Pathog. 2010 Dec 9;2(1):19

75. Ortiz-Lucas M, Saz-Peiró P, Sebastián-Domingo JJ: Irritable bowel syndrome immune hypothesis. Part one: the role of lymphocytes and mast cells. Rev Esp Enferm Dig. 2010 Nov;102(11):637-47.

76. Fandiño OR, Ruiz JH, Schmulson M.: From Cytokines to Toll-Like Receptors and Beyond -Current Knowledge and Future Research Needs in Irritable Bowel Syndrome. J Neurogastroenterol Motil. 2010 (4): 363–373.

77. Collins SM, Denou E, Verdu EF, Bercik P.: The putative role of the intestinal microbiota in the irritable bowel syndrome. Dig Liver Dis. 2009 Dec;41(12):850-3

78. Ohman L, Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 2010 Mar;7(3):163-73.

79. Brint EK, Macsharry J, Fanning A, Shanahan F, Quigley EM. Differential Expression of Toll-Like Receptors in Patients With Irritable Bowel Syndrome. Am J Gastroenterol. 2010 Nov 23

80. Bolino CM, Bercik P. Pathogenic factors involved in the development of irritable bowel syndrome: focus on a microbial role. Infect Dis Clin North Am. 2010; 24 (4): 961-75

81. Malinen E, Krogius-Kurikka L, Lyra A, Nikkilä J, Jääskeläinen A, Rinttilä T, Vilpponen-Salmela T, von Wright AJ, Palva A. Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome. World J Gastroenterol. 2010 Sep 28;16(36):4532-40.

82. Salonen A, de Vos WM, Palva A.: Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology. 2010 Nov;156(Pt 11):3205-15

83. Cremon C, Carini G, De Giorgio R, Stanghellini V, Corinaldesi R, Barbara G.: Intestinal dysbiosis in irritable bowel syndrome: etiological factor or epiphenomenon? Expert Rev Mol Diagn. 2010;10(4):389-93.

84. Craig OF, Quigley EM.: Bacteria, genetics and irritable bowel syndrome. Expert Rev Gastroenterol Hepatol. 2010 Jun;4(3):271-6.

85, Lee KJ, Tack J.: Altered intestinal microbiota in irritable bowel syndrome. Neurogastroenterol Motil. 2010; 22 (5): 493-8.

86. Parkes GC, Sanderson JD, Whelan K.: Treating irritable bowel syndrome with probiotics: the evidence. Proc Nutr Soc. 2010; 69 (2): 187-94

87. Codling C, O'Mahony L, Shanahan F, Quigley EM, Marchesi JR. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci. 2010 Feb;55(2):392-7

88. Quigley EM. Do Patients with Functional Gastrointestinal Disorders have an Altered Gut Flora? Therap Adv Gastroenterol. 2009 Jul;2(4):23-30.

89. Liebregts T., Adam B., Bredack C., Roth A., Heinzel S., Lester S. et al. (2007) Immune activation in patients with irritable bowel syndrome. Gastroenterology 132:913–920

90. McKeown E.S., Parry S.D., Stansfield R., Barton J.R., Welfare M.R. (2006) Postinfectious irritable bowel syndrome may occur after non-gastrointestinal and intestinal infection. Neurogastroenterol Motil 18:839–843

91. Marshall J.K., Thabane M., Borgaonkar M.R., James C. (2007) Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen. Clin Gastroenterol Hepatol 5:457–460

92. Mearin F., Perez-Oliveras M., Perello A., Vinyet J., Ibaez A., Coderch J. et al. (2005) Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology 129:98–104

93. Neal K.R., Barker L., Spiller R.C. (2002) Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut 51:410–413

94. Quigley E.M. (2007) A 51-year-old with irritable bowel syndrome: test or treat for bacterial overgrowth? Clin Gastroenterol Hepatol 5:1140–1143

95. Vanner S. (2008a) The lactulose breath test for diagnosing SIBO in IBS patients: another nail in the coffin. Am J Gastroenterol 103:964–965

96. Mayer EA, Tillisch K. The Brain-Gut Axis in Abdominal Pain Syndromes. Annu Rev Med. 2010 Jan 27

97. Johansson PA, Farup PG, Bracco A, Vandvik PO: How does comorbidity affect cost of health care in patients with irritable bowel syndrome? A cohort study in general practice. BMC Gastroenterol. 2010 Mar 17;10:31.

98. Chang JY, Locke GR 3rd, McNally MA, Halder SL, Schleck CD, Zinsmeister AR, Talley NJ. Impact of functional gastrointestinal disorders on survival in the community. Am J Gastroenterol. 2010 Apr;105(4):822-32

99. Hanevik K, Dizdar V, Langeland N, Hausken T. Development of functional gastrointestinal disorders after Giardia lamblia infection. BMC Gastroenterol. 2009 Apr 21;9:27.

100. Compare D, Pica L, Rocco A, De Giorgi F, Cuomo R, Sarnelli G, Romano M, Nardone G Effects of long-term PPI treatment on producing bowel symptoms and SIBO Eur J Clin Invest. 2010 Dec 3

101. Grundmann O, Yoon SL, Moshiree B Current Developments for the Diagnosis and Treatment of Irritable Bowel Syndrome. Curr Pharm Des. 2010 Dec 3.

102. Di Stefano M, Tana P, Mengoli C, Miceli E, Pagani E, Corazza GR. Colonic hypersensitivity is a major determinant of the efficacy of bloating treatment in constipation-predominant irritable bowel syndrome. Intern Emerg Med. 2010 Dec 16

103. Quigley EM. Germs, gas and the gut; the evolving role of the enteric flora in IBS. Am J Gastroenterol. 2006 Feb;101(2):334-5.

104. Agrawal A, Houghton LA, Reilly B, Morris J, Whorwell PJ. Bloating and distension in irritable bowel syndrome: the role of gastrointestinal transit. Am J Gastroenterol. 2009 Aug;104(8):1998-2004

105. Goral V, Kucukoner M, Buyukbayram H.: Mast cells count and serum cytokine levels in patients with irritable bowel syndrome. Hepatogastroenterology. 2010 Jul-Aug;57(101):751- 4.

106. Korkut E, Bektas M, Oztas E, Kurt M, Cetinkaya H, Ozden A The prevalence of celiac disease in patients fulfilling Rome III criteria for irritable bowel syndrome. Eur J Intern Med. 2010 Oct;21(5):389-92. Epub 2010 Jul 14.

107. Kerckhoffs AP, Akkermans LM, de Smet MB, Besselink MG, Hietbrink F, Bartelink IH, Busschers WB, Samsom M, Renooij W.: Intestinal permeability in irritable bowel syndrome patients: effects of NSAIDs. Dig Dis Sci. 2010 Mar;55(3):716-23. Epub 2009 Mar 3.

Randomizowane badania kliniczne, metaanalizy i opinie ekspertów, w których wykazano korzyść dla pacjentów ze stosowania probiotyku Lactobacillus plantarum 299v  (DSM 9843) w zespole jelita nadwrażliwego

Ducrotté P, Sawant P, Jayanthi V.: Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. 

World J Gastroenterol. 2012 14;18 (30): 4012-8 Pełny tekst: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419998/pdf/WJG-18-4012.pdf

Layer P, Andresen V, Pehl C i wsp.; Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten; Deutschen Gesellschaft für Neurogastroenterologie und Motilität: Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management. Z Gastroenterol. 2011 Feb;49(2):237-93
Andresen V, Keller J, Pehl C, Schemann M, Preiss J, Layer P: Irritable bowel syndrome-the main recommendations. Dtsch Arztebl Int. 2011 Nov;108(44):751-60
Pełny tekst:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226958/pdf/Dtsch_Arztebl_Int-108-0751.pdf


Ford AC, Quigley EM, Lacy BE, Lembo AJ i wsp.: Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Saito YA, Schiller LR, Soffer EE, Spiegel BM, Moayyedi P.
Am J Gastroenterol. 2014; 109 (10):1547-61


Floch MH, Walker WA, Sanders ME, Nieuwdorp M i wsp.: Recommendations for Probiotic Use - 2015 Update: Proceedings and Consensus Opinion. J Clin Gastroenterol. 2015; 49 Suppl 1: S69-73
Floch MH. Recommendations for probiotic use in humans-a 2014 update. Pharmaceuticals (Basel). 2014 Oct 10;7(10):999-1007
Pełny tekst: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210857/pdf/pharmaceuticals-07-00999.pdf

 

Jiménez MB: Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last? Rev Esp Enferm Dig (Madrid) 2009, Vol. 101, 8, 553-564

Niedzielin K, Kordecki H, Birkenfeld B.: A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2001; 13 (10): 1143-7

Nobaek S, Johansson ML, Molin G, Ahrné S, Jeppsson B: Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol. 2000; 95 (5): 1231-8.

Johansson, M-L., Nobaek, S., Berggren, A., Nyman, M., Björck, I., Ahrné, S., Jeppsson, B.,
and Molin, G. (1998). Survival of Lactobacillus plantarum DSM 9843 (299v), and effect on the short-chain fatty acid content in faeces after ingestion of a rose-hip drink with fermented oats. Int. J. Fd. Microbiol. 42: 29-38

Prace, w których wykazano korzystne działanie szczepu Lactobacillus plantarum 299v w profilaktyce powikłań związanych z przyjmowaniem antybiotyków:

Kujawa-Szewieczek A, Adamczak M, Kwiecień K, Dudzicz S, Gazda M, Więcek A.:
The Effect of Lactobacillus plantarum 299v on the Incidence of Clostridium difficile Infection in High Risk Patients Treated with Antibiotics.
Nutrients. 2015 Dec 4;7(12): 10179-88


Lönnermark E, Friman V, Lappas G, Sandberg T, Berggren A, Adlerberth I.: Intake of Lactobacillus plantarum reduces certain gastrointestinal symptoms during treatment
with antibiotics. J Clin Gastroenterol. 2010 Feb;44(2):106-12


Klarin B, Wullt M, Palmquist I, Molin G, Larsson A, Jeppsson B.: Lactobacillus plantarum 299v reduces colonisation of Clostridium difficile in critically ill patients treated with antibiotics. Acta Anaesthesiol Scand. 2008 Sep;52(8):1096-102


Wullt M, Johansson Hagslätt ML, Odenholt I, Berggren A.: Lactobacillus plantarum 299v enhances the concentrations of fecal short-chain fatty acids in patients with recurrent clostridium difficile-associated diarrhea. Dig Dis Sci. 2007 Sep;52(9):2082-6


Wullt, M., Johansson Hagslätt, M.-L. and Odenholt, I: Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficille-associated diarrhoea: A double blind placebo-controlled trial. Scandinavian Journal of Infect., 2003: Dis. 35: 365-367

Prace, w których opisano mechanizm działania szczepu Lactobacillus plantarum 299v

Hulst M, Gross G, Liu Y, Hoekman A, Niewold T, van der Meulen J, Smits M.: Oral administration of Lactobacillus plantarum 299v modulates gene expression in the ileum
of pigs: prediction of crosstalk between intestinal immune cells and sub-mucosal adipocytes. Genes Nutr. 2015; 10 (3): 461
Pełny tekst: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393378/pdf/12263_2015_Article_461.pdf


Kok J, Johansen E, Kleerebezem M, Teusink B: Lactic Acid Bacteria: embarking on 30 more years of research. Microb Cell Fact. 2014;13 Suppl 1:I1
Pełny tekst:  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155817/pdf/1475-2859-13-S1-I1.pdf

 

 

Randomizowane badania kliniczne, metaanalizy i opinie ekspertów, w których wykazano korzyść dla pacjentów ze stosowania probiotyku Lactobacillus plantarum 299v  (DSM 9843)
w zespole jelita nadwrażliwego

Ducrotté P, Sawant P, Jayanthi V.: Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. 
World J Gastroenterol. 2012 14;18 (30): 4012-8
Pełny tekst: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419998/pdf/WJG-18-4012.pdf

Layer P, Andresen V, Pehl C i wsp.; Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten; Deutschen Gesellschaft für Neurogastroenterologie und Motilität: Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management. Z Gastroenterol. 2011 Feb;49(2):237-93

Andresen V, Keller J, Pehl C, Schemann M, Preiss J, Layer P: Irritable bowel syndrome-the main recommendations. Dtsch Arztebl Int. 2011 Nov;108(44):751-60
Pełny tekst:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226958/pdf/Dtsch_Arztebl_Int-108-0751.pdf

Ford AC, Quigley EM, Lacy BE, Lembo AJ i wsp.: Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Saito YA, Schiller LR, Soffer EE, Spiegel BM, Moayyedi P.
Am J Gastroenterol. 2014; 109 (10):1547-61

Floch MH, Walker WA, Sanders ME, Nieuwdorp M i wsp.: Recommendations for Probiotic Use - 2015 Update: Proceedings and Consensus Opinion. J Clin Gastroenterol. 2015; 49 Suppl 1: S69-73

Floch MH. Recommendations for probiotic use in humans-a 2014 update.
Pharmaceuticals (Basel). 2014 Oct 10;7(10):999-1007
Pełny tekst: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210857/pdf/pharmaceuticals-07-00999.pdf

Jiménez MB: Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last? Rev Esp Enferm Dig (Madrid) 2009, Vol. 101, 8, 553-564

Niedzielin K, Kordecki H, Birkenfeld B.: A controlled, double-blind, randomized study
on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome.
Eur J Gastroenterol Hepatol. 2001; 13 (10): 1143-7

Nobaek S, Johansson ML, Molin G, Ahrné S, Jeppsson B: Alteration of intestinal microflora
is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome.
Am J Gastroenterol. 2000; 95 (5): 1231-8.

 

Johansson, M-L., Nobaek, S., Berggren, A., Nyman, M., Björck, I., Ahrné, S., Jeppsson, B.,
and Molin, G. (1998). Survival of Lactobacillus plantarum DSM 9843 (299v), and effect
on the short-chain fatty acid content in faeces after ingestion of a rose-hip drink with fermented oats.
Int. J. Fd. Microbiol. 42: 29-38

 

Prace, w których wykazano korzystne działanie szczepu Lactobacillus plantarum 299v
w profilaktyce powikłań związanych z przyjmowaniem antybiotyków:
 

Kujawa-Szewieczek A, Adamczak M, Kwiecień K, Dudzicz S, Gazda M, Więcek A.:
The Effect of Lactobacillus plantarum 299v on the Incidence of Clostridium difficile Infection in High Risk Patients Treated with Antibiotics.
Nutrients. 2015 Dec 4;7(12): 10179-88

Lönnermark E, Friman V, Lappas G, Sandberg T, Berggren A, Adlerberth I.: Intake of Lactobacillus plantarum reduces certain gastrointestinal symptoms during treatment
with antibiotics.
J Clin Gastroenterol. 2010 Feb;44(2):106-12

Klarin B, Wullt M, Palmquist I, Molin G, Larsson A, Jeppsson B.: Lactobacillus plantarum 299v reduces colonisation of Clostridium difficile in critically ill patients treated with antibiotics. Acta Anaesthesiol Scand. 2008 Sep;52(8):1096-102

Wullt M, Johansson Hagslätt ML, Odenholt I, Berggren A.: Lactobacillus plantarum 299v enhances the concentrations of fecal short-chain fatty acids in patients with recurrent clostridium difficile-associated diarrhea. Dig Dis Sci. 2007 Sep;52(9):2082-6

Wullt, M., Johansson Hagslätt, M.-L. and Odenholt, I: Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficille-associated diarrhoea: A double blind placebo-controlled trial. Scandinavian Journal of Infect., 2003: Dis. 35: 365-367

 

Prace, w których opisano mechanizm działania szczepu Lactobacillus plantarum 299v 

Hulst M, Gross G, Liu Y, Hoekman A, Niewold T, van der Meulen J, Smits M.: Oral administration of Lactobacillus plantarum 299v modulates gene expression in the ileum
of pigs: prediction of crosstalk between intestinal immune cells and sub-mucosal adipocytes.
Genes Nutr. 2015; 10 (3): 461
Pełny tekst: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393378/pdf/12263_2015_Article_461.pdf

Kok J, Johansen E, Kleerebezem M, Teusink B: Lactic Acid Bacteria: embarking on 30 more years of research. Microb Cell Fact. 2014;13 Suppl 1:I1
Pełny tekst:  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155817/pdf/1475-2859-13-S1-I1.pdf